Ad hoc announcement pursuant to Art. 53 LR Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner. Burgdorf, 09.12.2022, 7 a.m. – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner. Ypsomed and Eli Lilly entered into an agreement in November 2020 to register and commercialize YpsoPump under Lilly's brand in the USA. During the last two years, Ypsomed has customised its insulin pump system for the US market. The company remains committed to the US pump market and will continue its development program. Ypsomed will therefore deepening discussions with other interested parties. YpsoPump is highly attractive for the US market, because of its form factors, prefilled cartridge, and its state-of-the-art and proven automated insulin delivery system. The commercial success of mylife Loop with YpsoPump in Europe demonstrates its high acceptance amongst people with diabetes. As a one-off effect in the financial year 2022/23, Ypsomed may have to depreciate development efforts in the single-digit million range. The EBIT target of CHF 90 million for the financial year 2023/24 remains unchanged. Download media release | 
